NHG is now licensed to provide mobile testing (shallow nostril swab) for COVID 19. Stay at home and REGISTER for your test! Currently available in the Northern Virginia area only.
$110 per test
Access Bio's CARESTART COVID-19 Antigen Rapid Test
UPDATED 2/1/21: FDA has authorized ANTERIOR NASAL SWAB collection. (Shallow nostril swab. See updated IFU at bottom)
RAPID POC TEST
The continuing spread of COVID-19 has raised the importance of rapid screening. Demand for rapid test kits is rising because unlike polymerase chain reaction (PCR) tests, they require no special equipment. Access Bio, Inc., the world’s leading manufacturer of rapid test kits for malaria, developed CareStart™ COVID-19 Ag to rapidly detect antigens of SARS-CoV-2, the virus which causes COVID-19..
Due to the highly contagious nature and global health crisis, SARS-CoV-2 has been designated as a pandemic by the World Health Organization (WHO) and continues to have devastating impacts on healthcare systems and the world economy including the U.S. To effectively end the SARS-CoV-2 pandemic, systematic screening and detection of both clinical and asymptomatic COVID-19 cases is critical.
The CareStart™ COVID-19 Antigen Test is a lateral flow immunochromatographic assay for the detection of extracted nucleocapsid protein antigens specific to SARS-CoV-2 in swab specimens directly collected from individuals who are suspected of COVID-19 by their healthcare providers. This product is CLIA waived under FDA/EUA authorization.
As an intended point-of-care (POC) designated COVID test with a 10 minute processing time, CareStart™ COVID-19 Antigen Test allows effective screening of COVID-19 infection on a large scale.
- Lateral flow assay
- Rapid results in 10 minutes
- Minimally invasive specimen collection (nasopharyngeal)
- Intended at POC setting (i.e., in patient care settings) by medical professionals
- Detect SARS-CoV-2 nucleocapsid protein antigen
- Identify acute infection with high sensitivity and 100% specificity
The CareStart™ COVID-19 Antigen Test is a lateral flow immunochromatographic assay for the detection of extracted nucleocapsid protein antigens specific to SARS-CoV-2 in swab specimens directly collected from individuals who are suspected of COVID-19 by their healthcare providers.
This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
The cost of this service is $110 per test. ALL Personal Protection Equipment (PPE) is provided by the Medical House.
*** This service is available in Virginia ONLY at this time.***
NPI #1265998264 CLIA #49D2212468